A recent clinical study suggested that cancer-specific survival differed significantly between adult patients with positive TFE3 rearrangement RCCs and adult patients with negative TFE3 rearrangement PRCC, which implied that adult RCCs with TFE3 rearrangement may be a clinically aggressive tumour9. This evidence concerns the gene TFE3 and cancer.